Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,631,359
  • Shares Outstanding, K 101,579
  • Annual Sales, $ 36,280 K
  • Annual Income, $ -481,190 K
  • EBIT $ -524 M
  • EBITDA $ -515 M
  • 60-Month Beta 1.81
  • Price/Sales 43.21
  • Price/Cash Flow N/A
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 83.31% ( -5.67%)
  • Historical Volatility 84.93%
  • IV Percentile 93%
  • IV Rank 73.53%
  • IV High 93.68% on 10/23/24
  • IV Low 54.50% on 08/21/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 1,261
  • Volume Avg (30-Day) 2,701
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 42,540
  • Open Int (30-Day) 32,536

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.37
  • Number of Estimates 13
  • High Estimate -1.06
  • Low Estimate -1.53
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +0.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.95 +14.48%
on 10/31/24
21.47 -25.62%
on 10/18/24
-1.87 (-10.48%)
since 10/07/24
3-Month
13.95 +14.48%
on 10/31/24
24.16 -33.90%
on 08/23/24
-5.34 (-25.06%)
since 08/07/24
52-Week
13.95 +14.48%
on 10/31/24
34.87 -54.20%
on 02/29/24
-13.52 (-45.85%)
since 11/07/23

Most Recent Stories

More News
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

NTLA : 16.06 (-0.11%)
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

There's nothing bearish at all about what it reported recently.

NTLA : 16.06 (-0.11%)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 16.06 (-0.11%)
This Beaten-Down Stock Could Soar by 354%, According to Wall Street

Maybe the Street is a bit too optimistic on this one.

NTLA : 16.06 (-0.11%)
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

NTLA : 16.06 (-0.11%)
12 High-Growth Stocks That Could Deliver Parabolic Returns

These 12 innovative companies could deliver exponential returns over the next quarter century.

NVDA : 148.35 (+1.88%)
NVTS : 2.22 (-3.48%)
VRTX : 503.90 (+2.08%)
RKLB : 13.80 (+5.75%)
LUNR : 9.90 (+19.85%)
SERV : 10.79 (+6.94%)
ACHR : 3.56 (+10.90%)
TSLA : 298.06 (+3.30%)
CRSP : 52.38 (+3.27%)
SOUN : 7.03 (+23.55%)
APLD : 7.77 (+9.90%)
TM : 178.51 (+1.92%)
Why Intellia Therapeutics Stock Plummeted by 20% Today

Seemingly encouraging results from the lab were met with some notable skepticism.

NTLA : 16.06 (-0.11%)
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

NTLA : 16.06 (-0.11%)
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.

NTLA : 16.06 (-0.11%)
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

NTLA : 16.06 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 17.06
2nd Resistance Point 16.65
1st Resistance Point 16.35
Last Price 16.06
1st Support Level 15.64
2nd Support Level 15.23
3rd Support Level 14.93

See More

52-Week High 34.87
Fibonacci 61.8% 26.88
Fibonacci 50% 24.41
Fibonacci 38.2% 21.94
Last Price 16.06
52-Week Low 13.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar